Matches in SemOpenAlex for { <https://semopenalex.org/work/W4240742457> ?p ?o ?g. }
- W4240742457 abstract "Abstract The principal focus of this chapter is on the epoxy compounds frequently encountered in industrial use as uncured epoxy resins. These resins are marketed in a variety of physical forms from low‐viscosity liquids to tack‐free solids and require admixture with curing agents to form hard and nonreactive cross‐linked polymers. They are in demand because of their toughness, high adhesive properties (polarity), low shrinkage in molds, and chemical inertness. It is the uncured resins that are of main interest to toxicologists, for a well‐cured resin should have few or no unreacted epoxide groups remaining in it. The toxicology of the curing agents is not treated in this chapter. They are most frequently bi‐ or trifunctional amines, di‐ or tricarboxylic acids and their anhydrides, polyols, and compounds containing mixed functional groups, such as aminols and amino acids, as well as other resins containing such groups. Some of the other epoxide compounds described in this chapter are used as reactive diluents in epoxy resin mixtures; others are of commercial importance for their multiple uses in the synthesis of other compounds (specifically, epichlorohydrin). As reactive diluents, monomeric epoxides are added to epoxy resins to reduce viscosity and modify the handling characteristics of the uncured materials. The epoxide functionalities of these diluents react with the resin curing agents in the same manner as the resin to become part of the finished polymer. Epoxy resins have found application as protective coatings, adhesives for most substrates (metals included), caulking compounds, flooring and special road paving, potting and encapsulation resins, low‐pressure molding mixtures, and binding agents for fiber glass products. Uncured, they are used as plasticizers and stabilizers for vinyl resins. Epoxy resin coating formulations can generally be limited to one of three forms: solution coatings, high‐solids formulations, and epoxy powder coatings. Solid epoxies are used in coating applications, as solid solutions or heat‐converted coating. Solution coatings are often room‐temperature applications, and typically there is little potential for vapor exposure. The potential clearly exists for skin contact during application of coatings of this type. Heat‐converted coatings are usually applied and cured by mechanical means and exposure to vapors or contact with skin is minimal. Solid resins are used for other applications such as electrical molding powders and decorative or industrial powder coatings. For applications of this kind, exposure to vapors and dust can occur and is greatest during formulating and grinding. Considering that epoxides can react with nucleophiles, particularly basic nitrogens, one might expect the epoxides to react with cellular biomolecules such as glutathione, proteins, and nucleic acids, and indeed this has been demonstrated for some of these epoxide compounds. The nature and magnitude of these interactions with these biomolecules is most likely related to the toxicity and observed for any given molecule in this class of compounds. However, the potential for any epoxide to react with cellular nucleophilic biomolecules is dependent on several factors, including the reactivity of the particular epoxide, the dose and dose rate, as well as the molecular weight, and solubility, these latter two influencing access to molecular targets within the cell. In addition, the efficiency of metabolism via epoxide hydrolase or other metabolic routes of detoxication may significantly influence the toxicologic potential and potency of these materials. Epoxide hydrolase activity is widely distributed throughout the body, but it is organ, species, and even strain variant. The liver, testes, lung, and kidney have considerable epoxide hydrolase activity; the activities in the skin and gut, however, are considerably lower. In this regard it should be noted that mouse tissues have a much lower level of EH activity than does human tissue; in fact, at least two strains of mice, C57BL/6N and DBA/2N, have no EH activity in their skins. Therefore, it may be questioned if toxicity or treatment‐related effects observed in dermal mouse studies are relevant for hazard evaluation. Epoxy compounds may also be metabolized by the cytoplasmic enzyme glutathione‐ S ‐transferase, which converts epoxides to 2‐alkylmercapturic acids. This enzyme because it is in the aqueous phase, may play a minor role in the detoxification of large lipophilic epoxides, but is active against low‐molecular‐weight epoxides. Due to differences in physio‐chemical properties and the effectiveness and nature of the detoxification of these materials through metabolism, the toxicity of these compounds ranges from the highly active, electrophilic, low‐molecular‐weight mono‐ and diepoxides to the nontoxic and inert cured materials, which possess only a few epoxy groups per molecule. In general, the acute toxicity of epoxy resin compounds as observed in laboratory animals can be considered low; oral and dermal LD 50 values generally range. Usually the irritating properties of epoxy liquids or vapors limit significant exposure to produce systemic toxicity. Effects most commonly observed in animals have been dermatitis (either primary irritation or secondary to induction of sensitization), eye irritation, pulmonary irritation, and gastric irritation, which are typically found in the tissues that are the first to come into contact with the epoxy compound. In general, it appears that epoxy compounds of higher molecular weight (e.g., epoxy novolac resins and diglycidyl ether of bisphenol A) produce less dermal irritation than those of lower molecular weight. In some instances, liquid epoxy compounds splashed directly into the eye may cause pain and, in severe cases, corneal damage. Skin irritation is usually manifested by more or less sharply localized lesions that develop rapidly on contact, more frequently on the arms and hands. Signs and symptoms usually include redness, swelling, and intense itching. In severe cases, secondary infections may occur. Workers show marked differences in sensitivity. Of the compounds in this chapter, four (resorcinol diglycidyl ether, epichlorohydrin, glycidaldehyde, and glycidol) were the subject of studies in which there was clear evidence of tumorigenic effects in rodents. Larger‐molecular‐weight glycidyloxy compounds such as castor oil glycidyl ether, the diglycidyl ether of bisphenol A, and advanced bisphenol A/epichlorohydrin epoxy resins have been negative in dermal bioassays. Epidemiology studies have not provided any evidence for an association between workplace exposure and cancer to any of the materials in this chapter." @default.
- W4240742457 created "2022-05-12" @default.
- W4240742457 creator A5068967286 @default.
- W4240742457 creator A5089960075 @default.
- W4240742457 date "2001-04-16" @default.
- W4240742457 modified "2023-10-09" @default.
- W4240742457 title "Epoxy Compounds—Aromatic Diglycidyl Ethers, Polyglycidyl Ethers, Glycidyl Esters, and Miscellaneous Epoxy Compounds" @default.
- W4240742457 cites W152910751 @default.
- W4240742457 cites W1963665810 @default.
- W4240742457 cites W1963667297 @default.
- W4240742457 cites W1965119826 @default.
- W4240742457 cites W1965254147 @default.
- W4240742457 cites W1967172867 @default.
- W4240742457 cites W1973160778 @default.
- W4240742457 cites W1975166861 @default.
- W4240742457 cites W1980999862 @default.
- W4240742457 cites W1981122858 @default.
- W4240742457 cites W1981696404 @default.
- W4240742457 cites W1988919190 @default.
- W4240742457 cites W1991090087 @default.
- W4240742457 cites W1992983738 @default.
- W4240742457 cites W1993823003 @default.
- W4240742457 cites W1994129885 @default.
- W4240742457 cites W1995198812 @default.
- W4240742457 cites W1995927451 @default.
- W4240742457 cites W1998552715 @default.
- W4240742457 cites W1998897262 @default.
- W4240742457 cites W2000515177 @default.
- W4240742457 cites W2004829369 @default.
- W4240742457 cites W2007348624 @default.
- W4240742457 cites W2007823219 @default.
- W4240742457 cites W2012850460 @default.
- W4240742457 cites W2017670635 @default.
- W4240742457 cites W2018324207 @default.
- W4240742457 cites W2019109379 @default.
- W4240742457 cites W2022585640 @default.
- W4240742457 cites W2022989338 @default.
- W4240742457 cites W2023617816 @default.
- W4240742457 cites W2025970141 @default.
- W4240742457 cites W2035813299 @default.
- W4240742457 cites W2036357329 @default.
- W4240742457 cites W2040770719 @default.
- W4240742457 cites W2041036438 @default.
- W4240742457 cites W2047442222 @default.
- W4240742457 cites W2050350173 @default.
- W4240742457 cites W2050732540 @default.
- W4240742457 cites W2053200717 @default.
- W4240742457 cites W2060174777 @default.
- W4240742457 cites W2063749950 @default.
- W4240742457 cites W2065247998 @default.
- W4240742457 cites W2067137053 @default.
- W4240742457 cites W2069066623 @default.
- W4240742457 cites W2071540375 @default.
- W4240742457 cites W2073174434 @default.
- W4240742457 cites W2074566595 @default.
- W4240742457 cites W2080199496 @default.
- W4240742457 cites W2083477696 @default.
- W4240742457 cites W2095590453 @default.
- W4240742457 cites W2101299705 @default.
- W4240742457 cites W2102339010 @default.
- W4240742457 cites W2114717315 @default.
- W4240742457 cites W2121990380 @default.
- W4240742457 cites W2130189678 @default.
- W4240742457 cites W2154993088 @default.
- W4240742457 cites W2155399387 @default.
- W4240742457 cites W2158785635 @default.
- W4240742457 cites W2161640159 @default.
- W4240742457 doi "https://doi.org/10.1002/0471435139.tox083" @default.
- W4240742457 hasPublicationYear "2001" @default.
- W4240742457 type Work @default.
- W4240742457 citedByCount "0" @default.
- W4240742457 crossrefType "other" @default.
- W4240742457 hasAuthorship W4240742457A5068967286 @default.
- W4240742457 hasAuthorship W4240742457A5089960075 @default.
- W4240742457 hasConcept C132976073 @default.
- W4240742457 hasConcept C154399059 @default.
- W4240742457 hasConcept C161790260 @default.
- W4240742457 hasConcept C166595027 @default.
- W4240742457 hasConcept C175804951 @default.
- W4240742457 hasConcept C178790620 @default.
- W4240742457 hasConcept C185592680 @default.
- W4240742457 hasConcept C188027245 @default.
- W4240742457 hasConcept C192562407 @default.
- W4240742457 hasConcept C2776920199 @default.
- W4240742457 hasConcept C2778925040 @default.
- W4240742457 hasConcept C2779227376 @default.
- W4240742457 hasConcept C521977710 @default.
- W4240742457 hasConcept C68928338 @default.
- W4240742457 hasConceptScore W4240742457C132976073 @default.
- W4240742457 hasConceptScore W4240742457C154399059 @default.
- W4240742457 hasConceptScore W4240742457C161790260 @default.
- W4240742457 hasConceptScore W4240742457C166595027 @default.
- W4240742457 hasConceptScore W4240742457C175804951 @default.
- W4240742457 hasConceptScore W4240742457C178790620 @default.
- W4240742457 hasConceptScore W4240742457C185592680 @default.
- W4240742457 hasConceptScore W4240742457C188027245 @default.
- W4240742457 hasConceptScore W4240742457C192562407 @default.
- W4240742457 hasConceptScore W4240742457C2776920199 @default.
- W4240742457 hasConceptScore W4240742457C2778925040 @default.
- W4240742457 hasConceptScore W4240742457C2779227376 @default.